Cullinan Therapeutics Doses First Patient in Phase 2 CLN-049 Study in Acute Myeloid Leukemia
MT newswire2026/10/08 11:3907:39 AM EDT, 10/08/2026 (MT Newswires) -- Cullinan Therapeutics (CGEM) said Thursday that the first patient has been dosed in its pivotal phase 2 study of CLN-049 in relapsed/refractory acute myeloid leukemia. The company said the study will evaluate CLN-049 in patients who have received up to two lines of prior therapy. The study also includes an exploratory cohort evaluating CLN-049 in patients with newly diagnosed TP53-mutated acute myeloid leukemia, according to a statement. Additionally, Cullinan said it is initiating a phase 1/2 study evaluating the combination of CLN-049, azacitidine, and venetoclax in patients with newly diagnosed acute myeloid leukemia.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
